heads of agreement - vueklar

Here's a few things worth highlighting from the announcement:

- "Significant target market size ($2b)"

- "The transaction will provide another pipeline for growth for the Company"

- "Their unique patent protected technology enables the non-invasive delivery and examination of any medical device in the body"

- "Peripheral arterial disease is a disease of the arteries outside the heart and brain that can lead to loss of a limb and can be life-threatening" (didn't someone say people's lives won't be depended on HepaFat? Well this could possible save lives)

- ". It is a significant and growing clinical problem due to ageing populations and the rise in cardiovascular risk factors, such as diabetes and obesity." (shows the company is looking towards the future and what people will need in the future, in an ageing population with more obese people)

- VueKlar has other applications outside of peripheral vascular disease which provides "additional commercialisation opportunities."

From what I've read, this acquisition definitely goes hand in hand with what the company believes in. More strings to their bow, for steady growth. Targeting the needs for future problems.

Also, although we might not know all too much about this acquisition just yet, but it certainly doesn't take away the fact that HepaFat is STILL ARTG listed and CE marked for sales. I think this would be a good time to capitalise on market's fear (fear of what they don't understand).